The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, Abramowicz D

Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab.

Transplantation 2003 Aug 15;76;459-63 — 2003 Aug 15 — 459-63

Barros VR, Rocha V, Garcia VD, Garcia CD

Anaphylactic shock after retreatment with basiliximab.

Transplantation proceedings 2003 Feb;35;579 — 2003 Feb — 579

Sisam DA, Sheehan JP

Tetracycline-responsive Yersinia-reactive arthritis: report of a case.

The Journal of the American Osteopathic Association 1987 Jul;87;493-5 — 1987 Jul — 493-5